Move from Bench to Bedside Faster
Pathology Evaluation in Tumorigenicity Studies
Learn how tumorgenicity studies can help you anticipate and overcome some of the challenges of advanced therapies with pathologist, Jimmy Tran.
Run time 10:00
Detection of Replication Competent Viruses in Viral Vector Products
Matthew Pennington, PhD, Scientist, Virology Department, Biologics Testing Solutions
Run time 14:01
Specialized CNS Endpoints
How do central nervous system endpoints affect the development of gene therapies? Our Head of Biomarkers and Molecular Imaging, Dr. Tuulia Huhtala, explains.
Run time: 3:30
ASO: The Essentials
Scientific Advisor Mike Templin explains the fundamentals of designing a nonclinical program for antisense oligonucleotides also known as nucleic acid-based therapies.
Run time: 12:00
COVID-19 Risk Mitigation Strategies for Cell and Gene Therapy Products - SARS-CoV-2 RT-PCR Assay for Biopharmaceutical Cell Substrate, Raw Materials, and Product Screening
Michael J. Hantman, Ph.D., Scientific Advisor, Biologics Testing Solutions
Run time: 17:04
Analytical Ultracentrifugation for Characterization of AAV Gene Delivery Vectors
Learn how the adeno-associated virus (AAV) vectors used to deliver gene therapies are characterized from Christopher Sucato, Associate Director of our Biophysical Laboratory in Shrewsbury, Massachusetts.
Run time 20:17
Importance of Donor Management for Successful Cell Therapies
An effective cell therapy depends on reliable, repeatable source material. Product owner Jordan Hunter explains earn why donor management is critical to your program.
Run time: 13:57
Viral Clearance Challenges for Gene Therapy Products
Tareq Jaber, Senior Manager, Process Evaluation, Biologics Testing Solutions
Run time 15:20
Rapid Virus Detection Platforms for Testing ATMP Products and Raw Materials
Michael J. Hantman, Ph.D., Scientific Advisor, Biologics Testing Solutions
Run time 16:56
Mass Spectrometry-Based Characterization of Adeno-Associated Viruses
Andrew Hanneman, PhD, Scientific Advisor, Biologics Testing, Biologics Testing Solutions
Run time 14:01
Importance of Source Material Consistency for Advancement of Cell Therapy
How can one ensure a consistent supply of high-quality starting material to support the research, development, and commercialization of cell and gene therapies? Our Director of Global Cell Therapy Strategy & Innovation, Dr. Dominic Clarke, explains.
Run time: 11:43
Biologics Testing for Cellular Therapy
Steven Miklasz, MSc, CBA, Advanced Therapy and Key Accounts Development Director, Biologics Testing Solutions
Run time: 08:51
Gene Therapy Studies (AAV Vector): Troubleshooting Considerations for Viral Clearance
Amanda Budzilowicz, MS, Research Associate 2 Process Evaluation, Biologics Testing Solutions.
Run time: 14:13
Quick Guide to ddPCR
Keith Sutton, PhD, gives an overview of ddPCR evaluations that supports the development of cell and gene therapies.
Run time: 14:40
Cell Therapy Regulatory Considerations
Shawna Jackman, Senior Principal Research Scientist, reviews regulatory considerations for safety assessment evaluations of cell therapies.
Run Time: 11:40
Digital Droplet PCR in the Regulated Bioanalytical Laboratory
Benjamin Moritz, PhD, Research Scientist II, reviews the advantages of ddPCR analysis over traditional PCR.
Run Time: 33:53